RESUMO
Loss-of-function mutations in the myotubularin gene (MTM1) cause X-linked myotubular myopathy (XLMTM), a fatal, congenital pediatric disease that affects the entire skeletal musculature. Systemic administration of a single dose of a recombinant serotype 8 adeno-associated virus (AAV8) vector expressing murine myotubularin to Mtm1-deficient knockout mice at the onset or at late stages of the disease resulted in robust improvement in motor activity and contractile force, corrected muscle pathology, and prolonged survival throughout a 6-month study. Similarly, single-dose intravascular delivery of a canine AAV8-MTM1 vector in XLMTM dogs markedly improved severe muscle weakness and respiratory impairment, and prolonged life span to more than 1 year in the absence of toxicity or a humoral or cell-mediated immune response. These results demonstrate the therapeutic efficacy of AAV-mediated gene therapy for myotubular myopathy in small- and large-animal models, and provide proof of concept for future clinical trials in XLMTM patients.
Assuntos
Modelos Animais de Doenças , Terapia Genética/métodos , Miopatias Congênitas Estruturais/genética , Miopatias Congênitas Estruturais/terapia , Animais , Dependovirus/genética , Diafragma , Cães , Vetores Genéticos , Genótipo , Células HEK293 , Humanos , Masculino , Camundongos , Camundongos Knockout , Contração Muscular , Debilidade Muscular , Mutação , Miopatias Congênitas Estruturais/mortalidade , Proteínas Tirosina Fosfatases não Receptoras/genéticaRESUMO
Polybrominated diphenyl ethers (PBDEs) and their methoxylated- (MeO-) and hydroxylated- (OH-) analogs are ubiquitously distributed in the environment worldwide. The OH-BDEs have greater potency than PBDEs and can be produced from the transformation of MeO-BDEs. The objectives of the current study were to (1) identify the enzyme(s) that catalyze biotransformation of 6-MeO-BDE-47 to 6-OH-BDE-47 in livers from rainbow trout, and (2) compare biotransformation of 6-MeO-BDE-47 to 6-OH-BDE-47 among rainbow trout, white sturgeon and goldfish. Cytochrome P450 1A (CYP1A) enzymes did not catalyze the biotransformation reaction. However, biotransformation was significantly inhibited by the CYP inhibitors clotrimazole and 1-benzylimidazole but not gestodene. Therefore, the reaction is likely catalyzed by CYP2 enzymes. When biotransformation was compared among species, concentrations of 6-OH-BDE-47 were significantly 3.4- and 9.1-fold greater in microsomes from rainbow trout compared to goldfish or white sturgeon, respectively. Concentrations of 6-OH-BDE-47 in microsomes from goldfish were non-significantly 2.7-fold greater than in sturgeon. The initial rate of biotransformation in microsomes from livers of rainbow trout was significantly 2.0- and 6.2-fold greater than the initial rate of biotransformation in microsomes from livers of goldfish or sturgeon, respectively, while the initial rate in goldfish was significantly 3.1-fold greater than in sturgeon. It is hypothesized that differences in CYP-mediated biotransformation of MeO-BDEs to OH-BDEs could influence concentrations of OH-BDEs in different species of fish.